In the present study, 46 phytochemicals of O. sanctum (Tulsi) were screened through in silico procedures for their ability to bind and inhibit BTK [PDB ID: 5P9J], a well-recognized drug target for chronic lymphocytic leukaemia (CLL) (Table 1). Here, BTK is linked to B-cell chronic lymphocytic leukemia.